Showing 34,101 - 34,120 results of 35,053 for search '(( 5 ((point decrease) OR (nn decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 1.02s Refine Results
  1. 34101

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  2. 34102

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  3. 34103

    Epidural Hydromorphone for Postpartum Pain Management After Vaginal Delivery: A Randomized Clinical Trial by Yixing Lu (19234084)

    Published 2025
    “…Postpartum analgesic medication requirements were reduced in the HY group (6.79% vs. 24.77%; OR 0.39, 95% CI 0.25-0.61), and the time to first additional analgesic was prolonged (15.63 ± 5.98 vs. 12.01 ± 5.01 h). However, the HY group exhibited increased rates of nausea and vomiting (26.24% vs. 8.11%; RR 1.72, 95% CI 1.45-2.04), dizziness (25.34% vs. 14.41%; RR 1.34, 95% CI 1.13-1.66), pruritus (32.58% vs. 7.21%; RR 1.95, 95% CI 1.67-2.28), and urinary retention (20.81% vs. 7.66%; RR 1.59, 95% CI 1.32-1.91). …”
  4. 34104

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  5. 34105

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  6. 34106

    Figure 3 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation by Anna Rutkowska (19676837)

    Published 2025
    “…<i>P</i> < 0.05, |log<sub>2</sub> fc| > log<sub>2</sub> (1.5)] modulated ones are indicated with name. Niraparib decreases CYP51A1 (lanosterol 14α-demethylase) enzyme levels (Supplementary Fig. …”
  7. 34107

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  8. 34108

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  9. 34109

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  10. 34110

    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  11. 34111

    Early dendritic protrusions of Fmr1 KO mice develop normally in vitro, except for a transiently elevated density at P4–7. by Alberto Cruz-Martín (331261)

    Published 2013
    “…Images are best projections (∼5–11 optical sections, 1 µm apart). Dendrites were imaged every 60 seconds, but only a subset of time points is shown. …”
  12. 34112

    Table_1_How, when, and to what degree do people with alcohol dependence recover their psychological wellbeing and quality of life? The Madrid Recovery Project.DOCX by Gabriel Rubio (4330366)

    Published 2023
    “…</p>Results<p>In general, according to the regression models, there were pronounced increases in indices of wellbeing and coping strategies (and pronounced decreases in negative emotionality) during the first 5 years of abstinence, followed by less pronounced improvements. …”
  13. 34113

    Datasheet3_Metabolic impact of feeding prior to a 60-min bout of moderate-intensity exercise in females in a fasted state.docx by Kayla M. Ratliff (14429421)

    Published 2023
    “…</p>Methods<p>Recreationally active females (n = 15, 32 ± 10 years, 164.8 ± 5.6 cm, 63.5 ± 9.3 kg, 23.4 ± 3.2 kg/m<sup>2</sup>) completed four testing sessions in a randomized, double-blind, crossover fashion after fasting overnight. …”
  14. 34114

    Data Sheet 1_Top motor and non-motor complaints in patients with Parkinson's disease.docx by José Fidel Baizabal-Carvallo (11416508)

    Published 2025
    “…The presence of non-motor symptoms in the top three tiers was associated with decreased cognitive status (MoCA <25 points), but not with age, sex, or disease evolution time. …”
  15. 34115

    Effects of Physical Activity Training in Patients with Alzheimer’s Dementia: Results of a Pilot RCT Study by Vjera A. Holthoff (351112)

    Published 2015
    “…</p><p>Methods</p><p>In an RCT thirty patients (aged 72.4±4.3 years) with AD (MMSE: 20.6±6.5 points) and their family caregivers were allocated to a home-based 12-week PA intervention program or the usual care group. …”
  16. 34116

    Datasheet4_Metabolic impact of feeding prior to a 60-min bout of moderate-intensity exercise in females in a fasted state.docx by Kayla M. Ratliff (14429421)

    Published 2023
    “…</p>Methods<p>Recreationally active females (n = 15, 32 ± 10 years, 164.8 ± 5.6 cm, 63.5 ± 9.3 kg, 23.4 ± 3.2 kg/m<sup>2</sup>) completed four testing sessions in a randomized, double-blind, crossover fashion after fasting overnight. …”
  17. 34117

    Image_1_The Role of Lactate Exercise Test and Fasting Plasma C-Peptide Levels in the Diagnosis of Mitochondrial Diabetes: Analysis of Clinical Characteristics of 12 Patients With M... by Yuan Zhao (336512)

    Published 2022
    “…In addition, patients with MD exhibited significantly higher mean plasma lactate levels immediately after exercise compared to patients with type 1 diabetes mellitus (T1DM) (8.39 ± 2.75 vs. 3.53 ± 1.47 mmol/L, p=0.003) and delayed recovery time after exercise (6.02 ± 2.65 vs. 2.17 ± 1.27 mmol/L, p=0.011). The optimal cut-off points identified were 5.5 and 3.4 mmol/L for plasma lactate levels immediately after and 30 minutes after exercise, respectively. …”
  18. 34118

    Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? by Julia Krämer (436881)

    Published 2017
    “…Questionnaires were completed at 5 different time points. Patients were stratified into 5 subgroups according to the presence of PML risk factors (prior immunosuppression, anti-JCV antibody status, treatment duration). …”
  19. 34119

    Datasheet1_Metabolic impact of feeding prior to a 60-min bout of moderate-intensity exercise in females in a fasted state.docx by Kayla M. Ratliff (14429421)

    Published 2023
    “…</p>Methods<p>Recreationally active females (n = 15, 32 ± 10 years, 164.8 ± 5.6 cm, 63.5 ± 9.3 kg, 23.4 ± 3.2 kg/m<sup>2</sup>) completed four testing sessions in a randomized, double-blind, crossover fashion after fasting overnight. …”
  20. 34120

    In the CE3b-group, the AgB-specific IL-4 response changed over time independently of therapy. by Linda Petrone (339785)

    Published 2021
    “…<p>Whole-blood test analysis at T1 (15 patients in the CE3b-group and in 14 patients in the CE4-group) and at T2 (5 patients in the CE3b-group and in 4 patients in the CE4-group). …”